IL-12 Delivery for Bladder Cancer Treatment
Author Information
Author(s): Wu Zhiyuan, Li Wei, Tan Melissa, How Faith Yuan Xin, Sadhasivan Haripriya, Mahendran Ratha, Wu Qinghui, Chiong Edmund
Primary Institution: National University of Singapore
Hypothesis
Can red blood cell-derived extracellular vesicles (RBCEVs) effectively deliver IL-12 minicircle plasmids to treat bladder cancer?
Conclusion
RBCEVs can safely and effectively deliver IL-12 minicircle plasmids, leading to reduced bladder cancer growth and enhanced immune responses.
Supporting Evidence
- RBCEVs were shown to effectively deliver IL-12 minicircle plasmids to bladder cancer cells.
- Intratumoral delivery of IL-12 minicircle-loaded RBCEVs significantly suppressed tumor growth.
- Treatment with IL-12 minicircle led to increased immune cell infiltration in tumors.
- RBCEV-mediated delivery resulted in higher IL-12 protein secretion compared to parental plasmids.
Takeaway
Scientists found a way to use tiny bubbles from red blood cells to deliver a special medicine that helps the body fight bladder cancer better.
Methodology
The study used RBCEVs to deliver IL-12 minicircle plasmids to bladder cancer cells and evaluated the effects on tumor growth and immune response in mice.
Limitations
The study was conducted in a subcutaneous bladder cancer model, which may not fully represent the human bladder environment.
Participant Demographics
C57BL/6 mice, aged 6-8 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website